Bioventus, Inc. ( (BVS) ) has released its Q1 earnings. Here is a breakdown of the information Bioventus, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bioventus, Inc. is a global company specializing in innovative products for active healing, primarily operating in the healthcare sector with a focus on pain treatments, surgical solutions, and restorative therapies.
In its first-quarter earnings report for 2025, Bioventus announced a 4.3% decline in reported revenue to $123.9 million, while organic revenue saw a 5.0% increase. The company also reported a reduced net loss of $0.04 per share compared to $0.08 in the previous year, alongside a 33% rise in non-GAAP earnings per share.
Key financial highlights include a decrease in adjusted EBITDA to $19.2 million, attributed to the divestiture of the Advanced Rehabilitation Business and planned growth investments. The company’s pain treatments and surgical solutions segments showed growth, while restorative therapies faced a decline due to the divestiture. Bioventus also entered a new distribution agreement with APEX Biologix and strengthened its leadership team.
Looking ahead, Bioventus reiterated its financial guidance for 2025, expecting net sales between $560 million and $570 million, adjusted EBITDA of $112 million to $116 million, and non-GAAP EPS of $0.64 to $0.68, reflecting significant growth expectations.
The company’s management remains optimistic about navigating the macroeconomic environment and achieving above-market revenue growth through diverse drivers, enhancing profitability, and accelerating cash flow to create shareholder value.